Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 137
Filter
2.
J Immunol ; 182(6): 3432-9, 2009 Mar 15.
Article in English | MEDLINE | ID: mdl-19265121

ABSTRACT

Mechanisms of B cell tolerance act during development in the bone marrow and periphery to eliminate or restrict autoreactive clones to prevent autoimmune disease. B cells in the spleens of mice that harbor anti-insulin BCR transgenes (125Tg) are maintained in a functionally silenced or anergic state by endogenous hormone, but it is not clear when and where anergy is induced. An in vitro bone marrow culture system was therefore used to probe whether small protein hormones, a critical class of autoantigens, could interact with the BCR to induce anergy early during B cell development. Upon exposure to insulin, anti-insulin (125Tg) immature B cells show similar hallmarks of anergy as those observed in mature splenic B cells. These include BCR down-regulation, impaired proliferative responses to anti-CD40, and diminished calcium mobilization upon stimulation with BCR-dependent and independent stimuli. Inhibition of calcineurin also results in reduced immature B cell proliferation in a similar manner, suggesting a potential mechanism through which reduced intracellular calcium mobilization may be altering cellular proliferation. Signs of impairment appear after short-term exposure to insulin, which are reversible upon Ag withdrawal. This suggests that a high degree of functional plasticity is maintained at this stage and that constant Ag engagement is required to maintain functional inactivation. These findings indicate that tolerance observed in mature, splenic 125Tg B cells is initiated by insulin in the developing B cell compartment and thus highlight an important therapeutic window for the prevention of insulin autoimmunity.


Subject(s)
Clonal Anergy/genetics , Gene Silencing , Insulin Antibodies/physiology , Insulin/immunology , Precursor Cells, B-Lymphoid/immunology , Precursor Cells, B-Lymphoid/metabolism , Animals , Bone Marrow Cells/cytology , Bone Marrow Cells/immunology , Bone Marrow Cells/metabolism , CD40 Antigens/immunology , CD40 Antigens/metabolism , Calcium Signaling/immunology , Cell Differentiation/immunology , Cell Line, Tumor , Cell Proliferation , Cells, Cultured , Insulin/metabolism , Insulin Antibodies/biosynthesis , Interleukin-7/physiology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Precursor Cells, B-Lymphoid/cytology
3.
Proc Natl Acad Sci U S A ; 105(29): 10090-4, 2008 Jul 22.
Article in English | MEDLINE | ID: mdl-18626021

ABSTRACT

A fundamental question is what are the molecular determinants that lead to spontaneous preferential targeting of specific autoantigens in autoimmune diseases, such as the insulin B:9-23 peptide sequence in type 1 diabetes. Anti-insulin B:9-23 T cell clones isolated from prediabetic NOD islets have a conserved Valpha-segment/Jalpha-segment, but no conservation of the alpha-chain N region and no conservation of the Vbeta-chain. Here, we show that the conserved T cell receptor alpha-chain generates insulin autoantibodies when transgenically or retrogenically introduced into mice without its corresponding Vbeta. We suggest that a major part of the mystery as to why islet autoimmunity develops relates to recognition of a primary insulin peptide by a conserved alpha chain T cell receptor.


Subject(s)
Autoantibodies/biosynthesis , Genes, T-Cell Receptor alpha , Insulin Antibodies/biosynthesis , Insulin/immunology , Adoptive Transfer , Animals , Base Sequence , Clone Cells/immunology , Conserved Sequence , DNA Primers/genetics , Female , Genes, T-Cell Receptor beta , Interferon-gamma/biosynthesis , Islets of Langerhans/immunology , Islets of Langerhans/pathology , Male , Mice , Mice, Inbred NOD , Mice, Knockout , Mice, SCID , Mice, Transgenic , Receptors, Antigen, T-Cell, alpha-beta/genetics , Receptors, Antigen, T-Cell, alpha-beta/metabolism , T-Lymphocytes/immunology
4.
Int J Cardiol ; 126(1): 53-61, 2008 May 07.
Article in English | MEDLINE | ID: mdl-17477992

ABSTRACT

BACKGROUND: Previous studies have demonstrated that decreased levels of circulating adiponectin correlate with endothelial dysfunction in peripheral arteries. However, the relationship between adiponectin levels and endothelial function in coronary arteries remains unclear. The goal of the present study was to determine whether circulating adiponectin concentrations are a useful predictor of coronary endothelial function. METHODS: Thirty-six consecutive non-diabetic patients with normal or mildly diseased coronary arteries were enrolled in this study. Coronary endothelial function was evaluated by coronary vascular response to acetylcholine (Ach). The relationship between coronary vasoreactivity and adiponectin or other biochemical or anthropometric parameters was investigated. The predictive value of adiponectin level for assessment of coronary endothelial dysfunction was assessed at the best cut-off point. RESULTS: In a simple regression analysis, log-transformed adiponectin concentrations positively correlated with the percent change in coronary blood flow (CBF) and coronary artery diameter (CAD) induced by Ach (r=0.62, p<0.0001; r=0.63, p<0.0001, respectively). Insulin resistance index (HOMA-R), body mass index, immunoreactive insulin, and triglycerides concentrations also significantly correlated with the percent change in CBF and CAD. However, in a multiple regression analysis, log-transformed adiponectin concentration was the only independent predictor of the percent change in CBF and CAD (p<0.0001; p<0.0001, respectively). Furthermore, patients with adiponectin concentrations <6.3 mg/L demonstrated coronary endothelial dysfunction with high specificity both in terms of CBF and CAD response (85%; 88%, respectively). CONCLUSIONS: Adiponectin is a better predictor of coronary endothelial function than other factors such as HOMA-R, body mass index, immunoreactive insulin, and triglycerides.


Subject(s)
Adiponectin/blood , Body Mass Index , Coronary Circulation/physiology , Coronary Vessels/physiology , Endothelium, Vascular/physiology , Insulin Antibodies/blood , Insulin Resistance/immunology , Triglycerides/blood , Aged , Biomarkers/blood , Female , Homeostasis/physiology , Humans , Insulin Antibodies/biosynthesis , Male , Middle Aged , Models, Cardiovascular , Predictive Value of Tests
5.
Expert Opin Investig Drugs ; 15(7): 743-62, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16787139

ABSTRACT

Administration of insulin by inhalation was first attempted > 50 years ago. At that time, little was known concerning effective delivery systems and insulin formulations. The recent development of pulmonary delivery systems for the administration of insulin is driven by the reluctance of patients and their providers to initiate insulin earlier in the course of Type 2 diabetes, the desire to reduce the number of daily insulin injections for both Type 1 and 2 patients, and the recent emphasis on intensified glycaemic control including postprandial glycaemic control. The deep lung is a unique mucosal tissue having a surface area of > 100 m2 and is readily accessible both to the external environment and to drug delivery, provided that appropriate conditions are met. There have been four mid- to late-phase pulmonary insulin programmes using modern inhalation devices that will be reported in this paper. The programmes differ in the choice of delivery systems, the formulations of insulin and reported bioavailability, pharmacokinetic and glucodynamic profiles and adverse events. However, all systems successfully deliver insulin to the deep lung and biological effectiveness compares favourably with injected subcutaneous insulins.


Subject(s)
Diabetes Mellitus/drug therapy , Drugs, Investigational/administration & dosage , Insulin/administration & dosage , Administration, Inhalation , Adult , Aerosols , Animals , Biological Availability , Blood Glucose/analysis , Clinical Trials, Phase III as Topic , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Drug Compounding , Drugs, Investigational/adverse effects , Drugs, Investigational/pharmacokinetics , Drugs, Investigational/therapeutic use , Female , Glycated Hemoglobin/analysis , Guinea Pigs , Humans , Hypoglycemia/chemically induced , Insulin/adverse effects , Insulin/pharmacokinetics , Insulin/therapeutic use , Insulin Antibodies/biosynthesis , Lung/physiology , Male , Metered Dose Inhalers , Microspheres , Middle Aged , Multicenter Studies as Topic , Powders , Prospective Studies , Randomized Controlled Trials as Topic , Rats , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use
7.
J Immunol ; 175(2): 1073-9, 2005 Jul 15.
Article in English | MEDLINE | ID: mdl-16002708

ABSTRACT

The highly selective nature of organ-specific autoimmune disease is consistent with a critical role for adaptive immune responses against specific autoantigens. In type 1 diabetes mellitus, autoantibodies to insulin are important markers of the disease process in humans and nonobese diabetic (NOD) mice; however, the Ag-specific receptors responsible for these autoantibodies are obscured by the polyclonal repertoire. NOD mice that harbor an anti-insulin transgene (Tg) (V(H)125Tg/NOD) circumvent this problem by generating a tractable population of insulin-binding B cells. The nucleotide structure and genetic origin of the endogenous kappa L chain (Vkappa or IgL) repertoire that pairs with the V(H)125Tg were analyzed. In contrast to oligoclonal expansion observed in systemic autoimmune disease models, insulin-binding B cells from V(H)125Tg/NOD mice use specific Vkappa genes that are clonally independent and germline encoded. When compared with homologous IgL genes from nonautoimmune strains, Vkappa genes from NOD mice are polymorphic. Analysis of the most frequently expressed Vkappa1 and Vkappa9 genes indicates these are shared with lupus-prone New Zealand Black/BINJ mice (e.g., Vkappa1-110*02 and 9-124) and suggests that NOD mice use the infrequent b haplotype. These findings show that a diverse repertoire of anti-insulin B cells is part of the autoimmune process in NOD mice and structural or regulatory elements within the kappa locus may be shared with a systemic autoimmune disease.


Subject(s)
Antibody Diversity/genetics , B-Lymphocyte Subsets/immunology , B-Lymphocyte Subsets/metabolism , Gene Rearrangement, B-Lymphocyte, Light Chain , Immunoglobulin kappa-Chains/genetics , Insulin Antibodies/genetics , Animals , Autoantibodies/biosynthesis , Autoantibodies/genetics , Base Sequence , Bone Marrow Cells/immunology , Bone Marrow Cells/metabolism , Genetic Predisposition to Disease , Immunoglobulin Variable Region/biosynthesis , Immunoglobulin Variable Region/genetics , Immunoglobulin kappa-Chains/biosynthesis , Insulin/metabolism , Insulin Antibodies/biosynthesis , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred NOD , Mice, Transgenic , Molecular Sequence Data , Multigene Family/immunology , Polymorphism, Genetic/immunology , Protein Binding/genetics , Protein Binding/immunology , Receptors, Antigen, B-Cell/metabolism
8.
J Immunol ; 174(2): 827-33, 2005 Jan 15.
Article in English | MEDLINE | ID: mdl-15634904

ABSTRACT

Loss of tolerance is considered to be an early event that is essential for the development of autoimmune disease. In contrast to this expectation, autoimmune (type 1) diabetes develops in NOD mice that harbor an anti-insulin Ig transgene (125Tg), even though anti-insulin B cells are tolerant. Tolerance is maintained in a similar manner in both normal C57BL/6 and autoimmune NOD mice, as evidenced by B cell anergy to stimulation through their Ag receptor (anti-IgM), TLR4 (LPS), and CD40 (anti-CD40). Unlike B cells in other models of tolerance, anergic 125Tg B cells are not arrested in development, and they enter mature subsets of follicular and marginal zone B cells. In addition, 125Tg B cells remain competent to increase CD86 expression in response to both T cell-dependent (anti-CD40) and T cell-independent (anti-IgM or LPS) signals. Thus, for anti-insulin B cells, tolerance is characterized by defective B cell proliferation uncoupled from signals that promote maturation and costimulator function. In diabetes-prone NOD mice, anti-insulin B cells in this novel state of tolerance provide the essential B cell contribution required for autoimmune beta cell destruction. These findings suggest that the degree of functional impairment, rather than an overt breach of tolerance, is a critical feature that governs B cell contribution to T cell-mediated autoimmune disease.


Subject(s)
B-Lymphocyte Subsets/immunology , B-Lymphocyte Subsets/metabolism , Cell Differentiation/immunology , Clonal Anergy/immunology , Diabetes Mellitus, Type 1/immunology , Insulin Antibodies/biosynthesis , Animals , Antigens, CD/biosynthesis , B-Lymphocyte Subsets/cytology , B7-2 Antigen , Cell Differentiation/genetics , Cell Movement/genetics , Cell Movement/immunology , Cells, Cultured , Clonal Anergy/genetics , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/pathology , Humans , Immunoglobulin M/biosynthesis , Immunoglobulin M/genetics , Insulin Antibodies/genetics , Lymphocyte Activation/genetics , Lymphocyte Activation/immunology , Membrane Glycoproteins/biosynthesis , Mice , Mice, Inbred C57BL , Mice, Inbred NOD , Mice, Transgenic , Spleen/immunology , Spleen/pathology , T-Lymphocytes/immunology
9.
J Immunol ; 173(11): 6603-10, 2004 Dec 01.
Article in English | MEDLINE | ID: mdl-15557150

ABSTRACT

Aiming to study the early stages of type 1 diabetes phenotype, before insulitis appears, we measured insulin autoantibodies (IAA) between 3 and 5 wk of age in the NOD mouse (early-IAA (E-IAA)). We report that IAA are found as early as at 3 wk of age, at weaning, and their expression is a quantal phenotype. Maternal autoantibody status influences this early phenotype, because animals of litters issued from IAA-positive ante partum mothers develop E-IAA with a significantly higher incidence than animals issued from IAA-negative mothers. These E-IAA represent synthesized rather than transplacental autoantibodies, as evidenced by higher levels in many offspring compared with maternal IAA, and negative as well as positive offspring in the same litters and it correlates with early diabetes onset, defining the first autoimmune window in diabetes pathogenesis. Therefore, autoimmune processes leading to type 1 diabetes initiate early in life, are influenced by maternal autoantibody status, and can be revealed by the presence of IAA. Our data suggest that the mechanisms responsible for the breakdown of self-tolerance are subjected not only to genetic predisposition, but also to the physiological status of the mother. Pathological progression to autoimmunity is marked by the presence of immunological windows relating early steps with final disease onset.


Subject(s)
Animals, Newborn/immunology , Autoantibodies/biosynthesis , Diabetes Mellitus, Type 1/immunology , Insulin Antibodies/biosynthesis , Prediabetic State/immunology , Age of Onset , Animals , Biomarkers/metabolism , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/pathology , Disease Progression , Female , Male , Maternal-Fetal Exchange/immunology , Mice , Mice, Inbred NOD , Phenotype , Prediabetic State/genetics , Prediabetic State/pathology , Predictive Value of Tests , Pregnancy
10.
Clin Exp Immunol ; 136(1): 56-9, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15030514

ABSTRACT

It has been suggested that maternal environment, in particular maternal autoantibodies, modify the risk of developing autoimmune diabetes in offspring. The aim of this study was to determine whether modification of maternal environment and maternal diabetes risk through immunization affects autoimmune diabetes risk in the progeny. The risk of developing insulin antibodies and of developing diabetes was determined in 113 female progeny of non obese diabetic (NOD) dams that were immunized with insulin, control antigen or vehicle before or during pregnancy. Although NOD dams immunized with insulin were rendered diabetes resistant (40% diabetes by age 36 weeks versus 100% in control dams), diabetes development in their female offspring (72%, 26/36) was similar to that in female offspring of dams immunized with glucagon (82%, 22/27) or vehicle (76%, 19/25). Furthermore, no significant differences in diabetes development or insulin autoantibody titres were observed between female progeny of insulin autoantibody positive NOD dams (82% diabetes by age 36 weeks, 18/22), insulin autoantibody negative NOD dams (75%, 41/55), and NOD dams that had antibodies against exogneous insulin (71%, 22/31). The findings suggest that modification of the maternal risk for autoimmune diabetes via antigen-specific immunization is not transferred to progeny and that fetal exposure to insulin autoantibodies does not increase the risk for diabetes development.


Subject(s)
Diabetes Mellitus, Experimental/immunology , Diabetes Mellitus, Type 1/immunology , Insulin Antibodies/biosynthesis , Pregnancy in Diabetics/immunology , Animals , Autoantibodies/biosynthesis , Female , Immunity, Maternally-Acquired , Insulin/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred NOD , Pregnancy
11.
J Immunol ; 172(1): 302-9, 2004 Jan 01.
Article in English | MEDLINE | ID: mdl-14688338

ABSTRACT

The skin is both an essential barrier for host defense and an important organ of immunity. In this study, we show that the application of cholera toxin to intact mouse skin induces and enhances autoimmune diseases affecting organs at distant anatomic sites, whereas its administration by the mucosal route has been reported to have the opposite effect. First, the CNS autoantigen myelin oligodendrocyte glycoprotein 35-55, when applied repeatedly with cholera toxin to the intact skin of healthy C57BL/6 mice, induced relapsing paralysis with demyelinating immunopathologic features similar to multiple sclerosis. Second, the application of cholera toxin in the absence of autoantigen exacerbated the severity of conventional experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein in CFA. Third, the application of cholera toxin to the intact skin of NOD/Lt mice, with or without insulin B peptide 9-23, exacerbated insulitis and T lymphocyte-derived IFN-gamma and IL-4 production in the islets of Langerhans, resulting in an increased incidence and rate of onset of autoimmune diabetes. The data presented in this study highlight the different outcomes of adjuvant administration by different routes. Because dermal application of cholera toxin, and other bacterial products with similar adjuvant activities, is being developed as a clinical vaccination strategy, these data raise the possibility that it could precipitate autoimmune disease in genetically susceptible humans.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Cholera Toxin/administration & dosage , Cholera Toxin/immunology , Diabetes Mellitus, Type 1/immunology , Encephalomyelitis, Autoimmune, Experimental/immunology , Skin/immunology , Skin/microbiology , Administration, Cutaneous , Amino Acid Sequence , Animals , Antibodies, Bacterial/biosynthesis , Diabetes Mellitus, Type 1/microbiology , Diabetes Mellitus, Type 1/pathology , Encephalomyelitis, Autoimmune, Experimental/microbiology , Encephalomyelitis, Autoimmune, Experimental/pathology , Female , Immunoglobulin G/biosynthesis , Insulin/administration & dosage , Insulin/immunology , Insulin Antibodies/biosynthesis , Islets of Langerhans/immunology , Islets of Langerhans/microbiology , Islets of Langerhans/pathology , Mice , Mice, Inbred C57BL , Mice, Inbred NOD , Molecular Sequence Data , Myelin Proteins , Myelin-Associated Glycoprotein/administration & dosage , Myelin-Associated Glycoprotein/immunology , Myelin-Oligodendrocyte Glycoprotein , Organ Specificity/immunology , Peptide Fragments/administration & dosage , Peptide Fragments/immunology , Severity of Illness Index , Skin/cytology , Vaccines, Combined/administration & dosage , Vaccines, Combined/immunology
12.
J Immunol ; 171(5): 2270-8, 2003 Sep 01.
Article in English | MEDLINE | ID: mdl-12928371

ABSTRACT

Early systemic treatment of nonobese diabetic mice with high doses of recombinant adeno-associated virus (rAAV) vector expressing murine IL-10 prevents type 1 diabetes. To determine the therapeutic parameters and immunological mechanisms underlying this observation, female nonobese diabetic mice at 4, 8, and 12 wk of age were given a single i.m. injection of rAAV-murine IL-10 (10(4), 10(6), 10(8), and 10(9) infectious units (IU)), rAAV-vector expressing truncated murine IL-10 fragment (10(9) IU), or saline. Transduction with rAAV-IL-10 at 10(9) IU completely prevented diabetes in all animals injected at all time points, including, surprisingly, 12-wk-old animals. Treatment with 10(8) IU provided no protection in the 12-wk-old injected mice, partial prevention in 8-wk-old mice, and full protection in all animals injected at 4 wk of age. All other treatment groups developed diabetes at a similar rate. The rAAV-IL-10 therapy attenuated pancreatic insulitis, decreased MHC II expression on CD11b+ cells, increased the population of CD11b+ cells, and modulated insulin autoantibody production. Interestingly, rAAV-IL-10 therapy dramatically increased the percentage of CD4+CD25+ regulatory T cells. Adoptive transfer studies suggest that rAAV-IL-10 treatment alters the capacity of splenocytes to impart type 1 diabetes in recipient animals. This study indicates the potential for immunomodulatory gene therapy to prevent autoimmune diseases, including type 1 diabetes, and implicates IL-10 as a molecule capable of increasing the percentages of regulatory cells in vivo.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Diabetes Mellitus, Type 1/immunology , Diabetes Mellitus, Type 1/prevention & control , Genetic Therapy/methods , Interleukin-10/genetics , Interleukin-10/therapeutic use , Receptors, Interleukin-2/biosynthesis , T-Lymphocyte Subsets/immunology , Adenoviridae/genetics , Animals , Antibody Formation/genetics , Autoantibodies/biosynthesis , CD4-Positive T-Lymphocytes/metabolism , Dependovirus/genetics , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/pathology , Dose-Response Relationship, Immunologic , Female , Genetic Vectors , Immunity, Cellular/genetics , Injections, Intramuscular , Insulin Antibodies/biosynthesis , Interleukin-10/biosynthesis , Islets of Langerhans/immunology , Islets of Langerhans/pathology , Mice , Mice, Inbred C57BL , Mice, Inbred NOD , Recombination, Genetic , T-Lymphocyte Subsets/metabolism , Time Factors
13.
Diabetes Care ; 25(5): 876-82, 2002 May.
Article in English | MEDLINE | ID: mdl-11978684

ABSTRACT

OBJECTIVE: The antibody responses to a novel rapid-acting insulin analog, insulin aspart (IAsp), and their potential clinical correlates were studied with a specifically developed method in 2,420 people with diabetes treated for up to 1 year with preprandial subcutaneous injections of IAsp. RESEARCH DESIGN AND METHODS: Circulating insulin antibodies were analyzed by radioimmunoassay with (125)I insulin or IAsp tracers and polyethylene glycol precipitation. Four multinational, open, parallel group studies were conducted in Europe and North America, with a total of 1,534 people with diabetes exposed to IAsp and 886 people exposed to human insulin (HI) as meal-related insulin for 6-12 months. RESULTS: Insulin antibodies specific to HI or IAsp were absent in a majority of patients throughout the 6- to 12-month study periods. A majority of the patients (64-68%) had antibodies cross-reacting between HI and IAsp when entering the studies, with baseline levels (means +/- SD of percent bound/total) of 16.6 +/- 16.3% in study 1 and 10.3 +/- 14.0% in study 4. In all four studies, cross-reactive antibodies increased in patients exposed to IAsp, with a maximum at 3 months, and thereafter there was a decline toward baseline levels at 9-12 months (levels at 3 and 12 months: 22.3 +/- 19.7 and 16.8 +/- 16.5% in study 1 and 21.5 +/- 21.9 and 16.9 +/- 17.4% in study 4). Antibody levels showed similar changes in people with type 1 and type 2 diabetes, and there was no consistent relationship between antibody formation and glycemic control or between antibody formation and safety in terms of adverse events. CONCLUSIONS: Treatment with IAsp is associated with an increase in cross-reactive insulin antibodies, with a subsequent fall toward baseline values, without any indication of clinical relevance because no effect on efficacy or safety could be identified.


Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/therapeutic use , Insulin Antibodies/biosynthesis , Insulin/therapeutic use , Adult , Aged , Cross Reactions , Diabetes Mellitus, Type 1/immunology , Diabetes Mellitus, Type 2/immunology , Female , Humans , Hypoglycemic Agents/immunology , Insulin/analogs & derivatives , Insulin/immunology , Insulin Antibodies/blood , Insulin Aspart , Male , Middle Aged , Time Factors , Treatment Outcome , White People
14.
Autoimmunity ; 33(3): 153-69, 2001 May.
Article in English | MEDLINE | ID: mdl-11683376

ABSTRACT

We demonstrate using physico-chemical techniques that insulin binds to glucagon with a Kd of 0.89 micromolar. While such binding is of little significance physiologically, it has important immunological consequences. Hormone binding is mirrored by specific binding between insulin antibody and glucagon antibody to form idiotype-antiidiotype complexes observable by Ouchterlony immunodiffusion and ELISA. These complexes may provide new insights into the formation of circulating immune complexes in diabetes. The insulin-glucagon complex is hyper-antigenic, inducing antibody production at concentrations that do not elicit immune responses from the individual hormones. The resulting immune response is not primarily against the individual hormones, but against the complex. In fact, all so-called insulin antibodies tested (rabbit, guinea pig, mouse and human) show substantially higher affinity for insulin-glucagon complex than for insulin alone, suggesting that this complex is the primary antigen in most, if not all, cases. These results lead to several testable predictions, including the possibility that glucagon antibody will bind to insulin receptors to cause type 2 (antibody mediated) insulin resistance.


Subject(s)
Antigens/metabolism , Glucagon/immunology , Glucagon/metabolism , Insulin Antibodies/biosynthesis , Insulin/immunology , Insulin/metabolism , Animals , Antibodies, Anti-Idiotypic/biosynthesis , Antigen-Antibody Complex/metabolism , Antigens/chemistry , Autoimmunity , Chemical Phenomena , Chemistry, Physical , Glucagon/chemistry , Guinea Pigs , Humans , Immunodiffusion , Immunoglobulin Idiotypes/biosynthesis , In Vitro Techniques , Insulin/chemistry , Kinetics , Macromolecular Substances , Mice , Rabbits , Receptor, Insulin/immunology , Receptor, Insulin/metabolism
15.
J Autoimmun ; 17(1): 1-6, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11488632

ABSTRACT

NOD mice spontaneously develop anti-insulin autoantibodies associated with the subsequent development of diabetes. NOD mice that express insulin autoantibodies at 8 weeks of age have a diabetes risk exceeding 90%, while mice that do not express autoantibodies by 16 weeks have a risk of less than 20%. NOD female mice expressed insulin autoantibodies more often than male mice (13/15+ vs. 6/15+). Autoantibodies characteristically developed between 8 and 20 weeks and then for most mice became negative at diabetes onset in NOD mice. In the diabetes-free strain NOR mice, spontaneous expression of insulin autoantibodies was observed in less mice (female 8/15+, male 3/10+) compared to NOD mice. The expression of autoantibodies was transient in NOR mice and followed the same time-course as for NOD mice and they were all negative by 28 weeks (without progression to diabetes). No correlation was found in NOR mice between the levels of autoantibodies and insulitis. The program of insulin autoantibody expression is regulated over approximately 5 months for both NOD and NOR mice with only NOD mice developing diabetes, indicating that depending upon genetic combination, the presence of insulin autoantibodies does not always predict diabetes development. In addition, this data is not consistent with the hypothesis that the time-course of autoantibodies simply reflects the destruction of beta-cells with development of diabetes.


Subject(s)
Autoantibodies/biosynthesis , Diabetes Mellitus, Type 1/immunology , Insulin Antibodies/biosynthesis , Mice, Inbred NOD/immunology , Animals , Autoantibodies/blood , Diabetes Mellitus, Type 1/etiology , Diabetes Mellitus, Type 1/pathology , Disease Progression , Female , Insulin Antibodies/blood , Islets of Langerhans/immunology , Islets of Langerhans/pathology , Male , Mice , Mice, Inbred C57BL , Prospective Studies , Species Specificity , Time Factors
16.
J Immunol ; 166(8): 5265-70, 2001 Apr 15.
Article in English | MEDLINE | ID: mdl-11290812

ABSTRACT

Intra- and intermolecular spreading of T cell responses to autoantigens has been implicated in the pathogenesis of autoimmune diseases. Therefore, we questioned whether T cell responses from subjects identified as at-risk (positive for autoantibody reactivity to islet proteins) for the development of type 1 diabetes, a cell-mediated autoimmune disease, would demonstrate intermolecular Ag spreading of T cell responses to islet cell proteins. Previously, we have demonstrated that by the time subjects develop type 1 diabetes, they have T cell responses to numerous islet proteins, whereas T cells from normal controls respond to a limited number of islet proteins. Initial testing of PBMC responses from 25 nondiabetic at-risk subjects demonstrated that 16 of the 25 subjects have PBMC responses to islet proteins similar to controls. Fourteen of these 16 subjects were available for follow-up. Eleven of the 14 developed T cell responses to increasing numbers of islet proteins, and 6 of these subjects developed type 1 diabetes. In the nine subjects who already demonstrated T cell Ag spreading at the initial visit, four were available for follow-up. Of these four, two had increases in T cell reactivity to islet proteins, while two maintained their initial levels of T cell reactivity. We also observed Ag spreading in autoantibody reactivity to islet proteins in nine of the 18 at-risk subjects available for follow-up. Our data strongly support the conclusion that intermolecular spreading of T cell and Ab responses to islet proteins occurs during the preclinical period of type 1 diabetes.


Subject(s)
Autoantigens/immunology , Diabetes Mellitus, Type 1/immunology , Prediabetic State/immunology , Adolescent , Adult , Autoantibodies/biosynthesis , Cells, Cultured , Child , Diabetes Mellitus, Type 1/enzymology , Diabetes Mellitus, Type 1/genetics , Female , Follow-Up Studies , Glutamate Decarboxylase/immunology , Humans , Insulin Antibodies/biosynthesis , Islets of Langerhans/enzymology , Islets of Langerhans/immunology , Isoenzymes/immunology , Longitudinal Studies , Lymphocyte Activation , Male , Membrane Proteins/immunology , Middle Aged , Prediabetic State/enzymology , Prediabetic State/genetics , Protein Tyrosine Phosphatase, Non-Receptor Type 1 , Protein Tyrosine Phosphatases/immunology , Receptor-Like Protein Tyrosine Phosphatases, Class 8 , T-Lymphocytes/immunology , T-Lymphocytes/metabolism
17.
Diabetes Res Clin Pract ; 49(1): 7-15, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10808058

ABSTRACT

The majority of young diabetics in India prefer to use low-cost bovine insulin for economic reasons. Therefore, the question of insulin antibody response to bovine insulin and its functional significance is still relevant in the Indian context. We assessed insulin antibody response in 52 young diabetics (type 1, n=25, malnutrition modulated form of diabetes, n=19 and fibrocalculous pancreatopathy (FCP) n=8) on bovine insulin therapy (mean duration 3.0+/-2.1 years) using an internationally standardised in-house radioligand assay. The functional significance of insulin antibody was assessed by calculating their affinity constant, maximum binding capacity and total insulin binding power by Scatchard analysis (type 1, n=14, malnutrition modulated form of diabetes, n=11). All the patients treated with bovine insulin showed high titers of insulin antibodies with S.D. score ranging from 5.1 to 42.0. No significant difference was observed in the mean S.D. score of insulin antibodies in the three diabetic groups. The mean daily insulin dose, maximum insulin binding capacity and total insulin binding power were significantly higher in type 1 when compared to the malnutrition modulated form of diabetes (36+/-8 vs. 26+/-11 IU/day, P<0.05; 9. 7+/-7.8 vs. 4.0+/-3.9 nmol/l, P=0.03 and 59+/-29 vs. 29+/-43, P=0.01, respectively). Insulin antibodies S.D. score and its affinity did not show significant relationship with daily insulin dose and glycemic control (HbAl) at admission. Only 24+/-7% variations in daily insulin requirement were accounted for by total insulin binding power. There was a significant inverse relationship between insulin antibody S.D. score and duration of insulin therapy (r=-0. 4172, P<0.0004). To conclude, insulin antibody response following bovine insulin therapy is not different among type 1, malnutrition modulated form of diabetes and FCP diabetes. The insulin antibody response to bovine insulin therapy does not contribute significantly to increase in daily insulin requirement in bovine insulin treated insulin requiring young diabetics.


Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Insulin Antibodies/biosynthesis , Insulin/therapeutic use , Adolescent , Adult , Age of Onset , Animals , Antibody Affinity , Binding, Competitive , Blood Glucose/analysis , Cattle , Child , Female , Glycated Hemoglobin/analysis , Humans , India , Insulin/administration & dosage , Insulin/immunology , Insulin Antibodies/blood , Insulin Antibodies/immunology , Iodine Radioisotopes/chemistry , Male , Nutritional Status , Regression Analysis , Sensitivity and Specificity , Statistics, Nonparametric
18.
Diabetes Care ; 20(7): 1172-5, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9203458

ABSTRACT

OBJECTIVE: To assess the insulin antibody (IA) response to human insulin (HI) therapy in women with gestational diabetes. RESEARCH DESIGN AND METHODS: IAs were measured by a competitive radiobinding assay in 50 women with gestational diabetes before and during treatment with HI and after delivery. At delivery, 15 maternal-cord blood sample pairs were analyzed for IA. As a reference, we searched for IA in 25 new-onset type I diabetic patients, before and at 3, 6, and 12 months after insulin therapy. RESULTS: Insulin autoantibodies (IAAs) were detected in 1 of 50 women with gestational diabetes and 4 of 16 type I diabetic patients (P < 0.05). At the end of pregnancy after 9.3 +/- 6.8 weeks on insulin therapy, 22 of 50 (44%) women with gestational diabetes became IA+ and 4 additional women were found to be positive 2 months postpartum. After 3 months on insulin, type I diabetic patients showed a higher rate of IA positivity (92%, P < 0.001). IA titers at the end of pregnancy were associated with the cumulative insulin dose (r = 0.29, P < 0.05). Postpartum, IA disappeared slowly in most IA+ women, but two women still showed IA 2 years after delivery Titers in cord blood were strongly related to those in maternal blood (r = 0.74, P < 0.01). The rate of adverse fetal outcome did not differ in IA and IA- mothers (27 vs. 40%, NS). CONCLUSIONS: HI is immunogenic, and a short course of HI therapy induces IA in approximately 50% of women with gestational diabetes and 92% of type I diabetic patients. In women with gestational diabetes, insulin dose is slightly associated with IA titers. These IAs apparently cross the placenta. Fetal outcome does not differ according to the maternal IA status, and IAs disappear gradually after delivery but may remain positive for 2 years after delivery.


Subject(s)
Diabetes, Gestational/immunology , Hypoglycemic Agents/immunology , Insulin Antibodies/biosynthesis , Insulin/immunology , Adolescent , Adult , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/immunology , Diabetes, Gestational/blood , Diabetes, Gestational/drug therapy , Female , Fetal Blood/immunology , Humans , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Insulin Antibodies/blood , Insulin Antibodies/immunology , Pregnancy , Pregnancy Outcome , Time Factors
19.
J Autoimmun ; 10(3): 287-92, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9218756

ABSTRACT

Insulin-dependent diabetes (IDD), being an autoimmune disease, offers several opportunities for immunological interventions that may result either in the reduction of disease severity or in delaying diabetes onset. Among the various experimental preventative approaches, parenteral immunization with islet-specific autoantigens appears to be practically simpler and promising. We have previously shown that immunization with insulin, insulin B chain and B chain epitope (p9-23), but not insulin A chain, in incomplete Freund's adjuvant (IFA) and in alum (with B chain) delayed/prevented diabetes onset in NOD mice. Here we demonstrate the protective efficacy of affinity purified GAD65 in IFA. While both insulin B chain and GAD65 significantly delayed the onset of diabetes (P=0.001), a recently described tyrosine phosphatase (IA-2) antigen did not (P=0.38). Interestingly, B chain immunization reduced the incidence of cyclophosphamide (CY)-accelerated diabetes by about 50-55%. We also provide further evidence that B chain, upon increased adsorption to alum, could improve on its protective capacity in NOD mice.


Subject(s)
Diabetes Mellitus, Type 1/prevention & control , Vaccination/methods , Animals , Autoantibodies/biosynthesis , Autoantigens/immunology , Diabetes Mellitus, Type 1/etiology , Diabetes Mellitus, Type 1/immunology , Disease Susceptibility , Female , Glutamate Decarboxylase/immunology , Injections, Subcutaneous , Insulin/administration & dosage , Insulin/immunology , Insulin Antibodies/biosynthesis , Islets of Langerhans/immunology , Membrane Proteins/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Inbred NOD , Protein Tyrosine Phosphatase, Non-Receptor Type 1 , Protein Tyrosine Phosphatases/immunology , Receptor-Like Protein Tyrosine Phosphatases, Class 8
20.
Dig Dis Sci ; 41(8): 1672-7, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8769300

ABSTRACT

Development of type 1 insulin-dependent diabetes mellitus has been recently reported in patients who underwent interferon-alpha (IFN-alpha) therapy because of chronic viral hepatitis. Furthermore IFN-alpha seems to be involved in the immunological events that lead to beta-cell destruction and development of type 1 diabetes. To evaluate whether IFN-alpha treatment could elicit an autoimmune response against beta-cell antigens, we determined the occurrence of islet cell antibodies and insulin autoantibodies in the sera of 60 patients with HCV- or HBV-related chronic hepatitis who had been treated with IFN-alpha for 6 or 12 months. The presence of antibodies against thyroglobulin, thyroid microsomal antigen, gastric parietal cells, and non-organ-specific antigens was also investigated. Insulin autoantibody positivity was observed in 2/60 (3.3%), 8/60 (13.3%), and 4/30 (13.3%) patients, before IFN-alpha treatment, and after 6 months and 12 months of therapy, respectively. None of the studied patients developed islet cell antibodies or type 1 diabetes. Before IFN-alpha therapy four patients showed thyroid autoantibodies and four others developed antibodies against thyroglobulin and/or thyroid microsomal antigen during the treatment. Coexistence of insulin autoantibodies and thyroid autoantibodies was observed in only two patients. Our results showed that IFN-alpha therapy in patients with chronic viral hepatitis is capable of inducing development of autoantibodies against insulin. This event seems to be not related to other autoimmune disorders.


Subject(s)
Hepatitis B/therapy , Hepatitis C/therapy , Insulin Antibodies/biosynthesis , Interferon Type I/adverse effects , Adolescent , Adult , Autoantibodies/analysis , Chronic Disease , Diabetes Mellitus, Type 1/etiology , Female , Fluorescent Antibody Technique, Indirect , Hepatitis B/immunology , Hepatitis C/immunology , Humans , Interferon Type I/therapeutic use , Islets of Langerhans/immunology , Male , Middle Aged , Recombinant Proteins , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...